Bladder cancer, also called urothelial bladder cancer or BLCA, is a major urinary tract malignancy with recurrence and mortality burden, and it is increasingly studied as an immunologically “cold” disease with znf737–cxcl10-driven immune exclusion and resistance to anti pd 1 therapy. It is a key setting for systemic treatment advances, including standard neoadjuvant cisplatin-based chemotherapy, expanding use of immune checkpoint inhibitors, pd 1/pd l1 blockade with limited efficacy, and newer enfortumab vedotin and antibody drug conjugates approaches. The disease is also a major focus of non-invasive diagnostics, especially urine-based assays such as ai augmented urine cytology, dna methylation profiling, genomic biomarker assays, protein peptide metabolite detection, rna biomarkers, and postoperative circulating tumor dna for adjuvant tailoring. Recent literature highlights immunosuppressive mechanisms involving cd39 and cd73 on T cells, aberrant hmgb3 upregulation, and translational nanomedicine strategies, including magnetically targeted nanomotors and other delivery platforms. In high-risk localized disease, neoadjuvant systemic therapy remains standard, and pathologic complete response is used as a validated surrogate endpoint after chemotherapy. Global clinical-trial analyses also emphasize unequal access to novel systemic therapies, while biomarker studies and urine-based diagnostics aim to improve early detection, prognosis, and treatment guidance.
Immune exclusion and immunosuppression
- The znf737–cxcl10 axis was reported to drive immune exclusion and resistance to anti pd 1 therapy in bladder cancer. (PMID:41785601)
- cd39 expression on T cells strongly correlated with an immunosuppressive environment in bladder cancer. (PMID:42018002)
- cd73 expression on T cells strongly correlated with an immunosuppressive environment in bladder cancer. (PMID:42018002)
- A 2026 Cancer Immunology, Immunotherapy study linked CD39/CD73-mediated immunosuppression to tumor aggressiveness in bladder cancer. (PMID:42018002)
Diagnosis and biomarkers
- A 2026 Biosensors review highlighted non-invasive urine-based early diagnosis for bladder cancer. (PMID:41892063)
- ai augmented urine cytology was presented as an emerging non-invasive diagnostic approach for bladder cancer. (PMID:41892063)
- dna methylation profiling, genomic biomarker assays, protein peptide metabolite detection, and rna biomarkers were discussed as urine-based diagnostic strategies. (PMID:41892063)
- Circulating biomarker-based diagnosis, prognosis, and treatment guidance were discussed for bladder cancer, including postoperative circulating tumor dna to tailor adjuvant approaches. (PMID:41933678)
Therapy and translational advances
- Neoadjuvant cisplatin-based chemotherapy was described as standard of care in bladder cancer, with pathologic complete response validated as a surrogate endpoint in high-risk localized genitourinary malignancy. (PMID:41774881)
- immune checkpoint inhibitors and pd 1/pd l1 therapies expand treatment options, but efficacy remains limited in bladder cancer. (PMID:41964855)
- enfortumab vedotin and antibody drug conjugates were highlighted as important newer systemic therapies in clinical trials. (PMID:41964855)
- A 2026 Journal of Controlled Release study described a squid tentacle-mimetic magnetically targeted nanomotor platform using fluorinated polyethyleneimine and pirarubicin for synergistic chemotherapy-immunotherapy. (PMID:41839262)
- A 2026 Journal of Nanobiotechnology review emphasized nanomedicine-enabled immunotherapeutic strategies and translational challenges in urinary system tumors. (PMID:41947122)
Molecular pathology and prognosis
- hmgb3 was reported to be aberrantly upregulated in bladder cancer and discussed as part of broader therapy resistance and cancer stemness biology. (PMID:41930588)
- A 2026 review in Oncology Reports framed HMGB3 as a pivotal orchestrator of therapy resistance in human malignancies, including bladder cancer. (PMID:41930588)
- Global clinical-trial analyses showed unequal access to novel systemic therapies for bladder cancer across regions. (PMID:41964855)